Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (NCT05819359)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Who can join: Review the eligibility criteria below.
Location: Barrow Neurological Institute — Phoenix, Arizona
Age range: 35 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (95 Sites)
Showing the first 25 of 95 sites.
- Barrow Neurological Institute — Phoenix, Arizona
- University of California San Diego — La Jolla, California
- Cedars-Sinai — Los Angeles, California
- University of Colorado — Aurora, Colorado
- Parkinson's Center and Movement Disorders of Boca Raton — Boca Raton, Florida
- University of Miami, Dept. of Neurology — Miami, Florida
- Renstar Medical Research — Ocala, Florida
- Morehouse School of Medicine — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- Rush University Medical Center — Chicago, Illinois
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
- University of Kansas Medical Center — Kansas City, Kansas
- University of Kentucky — Lexington, Kentucky
- University of Maryland Medical Center — Baltimore, Maryland
- Baylor University Medical Center — Baltimore, Maryland
- The Johns Hopkins University School of Medicine — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Quest Research Institute, LLC — Farmington Hills, Michigan
- Mayo Clinic — Rochester, Minnesota
- Struthers Parkinson's Center- East — Saint Paul, Minnesota
- Park Nicollet Struther's Parkinson's Center (Struthers Parkinsons Center at HealthPartners) — Saint Paul, Minnesota
- Robert Wood Johnson Medical School — New Brunswick, New Jersey
- Icahn School of Medicine at Mount Sinai Beth Israel — New York, New York
- Weil Cornell Medical Center — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson's Disease
- Genotypic Influences on Network Progression in Parkinson's Disease — Manhasset, New York
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Phoenix, Arizona
- Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease — New Haven, Connecticut
- Cont. of a Study to Evaluate Implanting Peripheral Nerve Grafts Into Subjects With Parkinson's Disease (PD) During DBS — Lexington, Kentucky
- ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease — Toronto, Ontario
Explore by condition: All Parkinson's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.